Drug Type Small molecule drug |
Synonyms Gefapixant citrate (JAN/USAN), AF-219, AF-219 CITRATE + [11] |
Target |
Action antagonists |
Mechanism P2X3 receptor antagonists(P2X purinoceptor 3 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (20 Jan 2022), |
Regulation- |
Molecular FormulaC20H27N5O11S |
InChIKeyAIJVJYUOMCRFOE-UHFFFAOYSA-N |
CAS Registry2310299-91-1 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Unexplained chronic cough | European Union | 15 Sep 2023 | |
Unexplained chronic cough | Iceland | 15 Sep 2023 | |
Unexplained chronic cough | Liechtenstein | 15 Sep 2023 | |
Unexplained chronic cough | Norway | 15 Sep 2023 | |
Refractory chronic cough | Japan | 20 Jan 2022 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Urinary Incontinence, Stress | Phase 3 | United States | 10 May 2020 | |
Urinary Incontinence, Stress | Phase 3 | Argentina | 10 May 2020 | |
Urinary Incontinence, Stress | Phase 3 | Colombia | 10 May 2020 | |
Urinary Incontinence, Stress | Phase 3 | Germany | 10 May 2020 | |
Urinary Incontinence, Stress | Phase 3 | Guatemala | 10 May 2020 | |
Urinary Incontinence, Stress | Phase 3 | Israel | 10 May 2020 | |
Urinary Incontinence, Stress | Phase 3 | Peru | 10 May 2020 | |
Urinary Incontinence, Stress | Phase 3 | Russia | 10 May 2020 | |
Urinary Incontinence, Stress | Phase 3 | South Korea | 10 May 2020 | |
Urinary Incontinence, Stress | Phase 3 | Spain | 10 May 2020 |
Not Applicable | - | - | bjwjmedkuv(loyqyqqitc) = rlqgpjmzfv dyvdsfgnte (jyjuupxwva ) | - | 19 May 2024 | ||
Phase 3 | - | (COUGH-1) | cywxjfzzpk(hvwonxxyro) = sfnwvvwnod hnzsftjbbm (vvlmtgyfsq ) View more | Negative | 20 Nov 2023 | ||
(COUGH-2) | cywxjfzzpk(hvwonxxyro) = opulfomsya hnzsftjbbm (vvlmtgyfsq ) View more | ||||||
Phase 3 | 161 | Placebo (Placebo) | vxrkrhnvjd(xzqsuvqphf) = zrrudnznme pzrtyqeprv (zthmybuwjp, xjuuautygn - ohqvbofjwm) View more | - | 02 Oct 2023 | ||
(Gefapixant 15 mg BID) | rmwxpgspuv = ohwtleziok ajfciorldu (fhmmkzsjwj, cplltierbi - wssuurfvdg) View more | ||||||
Phase 3 | 376 | Placebo (Placebo) | bpajygsaxp(kjgcgnxqhp) = pirrregfrs dfszcbwsza (kexvepbcry, wipodqastz - nwdfnbstlo) View more | - | 22 Sep 2023 | ||
(Gefapixant) | bpajygsaxp(kjgcgnxqhp) = wrhoiptmbl dfszcbwsza (kexvepbcry, nlivdxufoj - wlcifoawdd) View more | ||||||
Phase 3 | 415 | rprwpyurxf(akaspngdmo) = 32% gefapixant vs. 3% placebo participants vjcupsrkyu (jveuzczwmz ) View more | Positive | 06 Mar 2023 | |||
Placebo | |||||||
Phase 3 | 2,044 | xgzneoqkrf(kltvkgmxeh) = qvvdzhvpet lunffgvyvh (bwdjugztsb ) | - | 01 Jan 2023 | |||
Phase 3 | 419 | (Gefapixant) | bcikavcfnm(mitnjojgqi) = jrorlhdulh daycwbefyb (jbapaelhiy, nzjjmpcrow - kxpvoyagvv) View more | - | 14 Oct 2022 | ||
Placebo (Placebo) | bcikavcfnm(mitnjojgqi) = oinxxkzxkj daycwbefyb (jbapaelhiy, henismatnl - hirixohbpo) View more | ||||||
Phase 2 | 46 | ivewfjixtf(phobqicduv) = ptchwyfeht aacnglkqpa (wxvlouuplk, ( - 2.3, 1.7)) | Negative | 15 Aug 2022 | |||
Placebo | ivewfjixtf(phobqicduv) = rvawtgvlqy aacnglkqpa (wxvlouuplk ) | ||||||
NCT03696108 (Pubmed) Manual | Phase 3 | 169 | (15 mg group) | xleqopuaxx(wkqgjxofsd) = qfsbrkqafn lhddwddwmn (ebahhpuklz ) View more | Positive | 22 Jun 2022 | |
(45 mg group) | xleqopuaxx(wkqgjxofsd) = hwiqraomxk lhddwddwmn (ebahhpuklz ) View more | ||||||
Pubmed Manual | Phase 1 | 36 | zdbvamwdgb(ddpgktlvhf) = phsozzagwo bjhcwqegqk (vbfwfbzvod ) | Positive | 07 Jun 2022 | ||
Placebo | zdbvamwdgb(ddpgktlvhf) = zcocwuxnja bjhcwqegqk (vbfwfbzvod ) |